Single-stent double-kissing nano-crush technique for the management of side branch ostial lesions: A game changer? Or just another player in the game?
Yükleniyor...
Dosyalar
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Kare Publishing
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
To the Editor,
We would like to thank the authors1
for reading and thoroughly analyzing our case
report.2
Isolated ostial side branch (SB) lesions, also known as Medina 0.0.1 lesions,
are among the most fascinating lesions in terms of percutaneous coronary procedures performed in coronary bifurcation lesions.3
Stenting the ostial lesion and
balloon angioplasty with atherectomy on the ostial lesion are the 2 main types of
percutaneous coronary interventional procedures for Medina 0.0.1 lesions in the
literature.4 The biggest argument against balloon-based treatment is that if ostial
lesions with a high tendency to dissect and recoil are not covered by a “stentscaffold,” it may increase the risk of target lesion revascularization and target vessel
revascularization.4 The “One Stent DOuble KIssing NAno CRUSH (OSDOKINA)
technique,” which we have outlined, has a number of potential advantages. The
ostial lesion is first to be entirely covered with a stent. Second, the major branch
has a nano-protruding SB stent. Third, nano-protruded stent components are
crushed in the main branch using an non-compliant balloon. There are 2 kissing balloon inflations to overcome the carina and plaque shift. Finally, a 1 : 1 sized
drug-eluted balloon is inflated at the main branch for 90 seconds at 14 atm to prevent balloon-induced barotrauma from causing main branch restenosis.
Açıklama
Anahtar Kelimeler
Medina 0.0.1 Lesions, One Stent DOuble KIssing NAno CRUSH (OSDOKINA)
Kaynak
Anatolian Journal of Cardiology
WoS Q Değeri
Q3
Scopus Q Değeri
Q3
Cilt
27
Sayı
10
Künye
Acar E, Güneş Y, İzgi İA, Kırma C. Reply to letter to the editor: “Single-stent double-kissing
nano-crush technique for the management of side branch ostial lesions: A game changer? Or just
another player in the game?” Anatol J Cardiol. 2023;27(10):613-614.
